-
Port Adelaide recruit Corey Durdin explains why he left Carlton and his special bond with sister
10 Jan 2026 05:25 GMT
… , rare genetic eye disease called Leber Congenital Amaurosis (LCA), 16-year-old Shianne …
-
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
08 Jan 2026 12:00 GMT
… .
OPGx-LCA5 – Gene Therapy for Leber Congenital Amaurosis (LCA)
Multiple regulatory designations granted … to address a form of Leber congenital amaurosis (LCA) due to biallelic mutations …
-
Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part C Cohort
08 Jan 2026 12:30 GMT
… -class, investigational gene therapy for Leber congenital amaurosis type 1 (LCA1) has completed …
-
<![CDATA[Positive pediatric data emerge from the OPGx-LCA5 phase 1/2 trial of Leber congenital amaurosis type 5]]>
02 Oct 2025 12:33 GMT
… , an investigational gene therapy for Leber congenital amaurosis type 5 (LCA5), an ultra … to address a form of Leber congenital amaurosis that results from biallelic mutations …
-
Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERION clinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10
01 Oct 2025 16:59 GMT
… , in individuals with CEP290- associated Leber Congenital Amaurosis Type 10 (LCA10).
“There are …
-
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
30 Sep 2025 11:00 GMT
… gene augmentation therapy for Leber congenital amaurosis type 5 (LCA5). … FDA. About Leber Congenital Amaurosis (LCA) and LCA5 Leber congenital amaurosis (LCA) is … inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and …
-
Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer
06 Jan 2026 12:30 GMT
… -class, investigational gene therapy for Leber congenital amaurosis type 1 (LCA1) has completed …
-
Gene therapy for Leber congenital amaurosis has positive phase 1/2 results at 12 months
26 Jun 2025 21:06 GMT
… -LCA5, a gene therapy for Leber congenital amaurosis.
She presented 12-month results … -LCA5 for the treatment of Leber congenital amaurosis, as Healio previously reported.
Sources …
-
Global Leber Congenital Amaurosis Market 2025-2034: Growth, Share, Segments & Emerging Trends Analysis
13 May 2025 17:14 GMT
… the Growth of the Leber Congenital Amaurosis Market?
The leber congenital amaurosis market is expected to … ;leber-congenital-amaurosis-global-market-report
How Is the Leber Congenital Amaurosis Market Segmented?
The leber congenital amaurosis …
-
FDA grants RMAT designation to gene therapy for Leber congenital amaurosis
08 May 2025 01:12 GMT
… -LCA5 for the treatment of Leber congenital amaurosis due to genetic variations in …
About
© 1995-2026